Interferon regulatory factor-1 expression in human uterine endometrial carcinoma

Gynecologic Oncology

Volumn 91, Issue 2, 2003, Pages 354-358

  Kuroboshi, Haruo ^a   Okubo, Tomoharu ^a   Kitaya, Kotaro ^a   Nakayama, Takeshi ^a   Daikoku, Nobue ^a   Fushiki, Shinji ^a   Honjo, Hideo ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Immunohistochemistry; Interferon regulatory factors (IRF 1); Tumor suppressor; Uterine endometrial carcinoma

Indexed keywords

CYTOKINE ANTIBODY; FORMALDEHYDE; INTERFERON REGULATORY FACTOR 1; PARAFFIN; POLYCLONAL ANTIBODY;

ADULT; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS;

EID: 0242321040     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00515-8     Document Type: Article

References (12)

1. Lowney J.K., Boucher L.D., Swanson P.E., Doherty G.M. Interferon regulatory factor-1 and -2 expression in human melanoma specimens. Ann Surg Oncol. 6:(6):1999;604-608.
2. Doherty G.M., Boucher L., Sorenson K., Lowney J. Interferon regulatory factor expression in human breast cancer. Ann Surg. 233:(5):2001;623-629.
3. Moriyama Y., Nishiguchi S., Tamori A., Koh N., Yano Y., Kubo S., et al. Tumor-supressor effect of interferon regulatory factor-1 in human hepatocellular carcinoma. Clin Cancer Res. 7:(5):2001;1293-1298.
4. Kitaya K., Yasuda J., Fushiki S., Honjo H. Localization of interferon regulatory factor-1 in human endometrium throughout the menstrual cycle. Fertil Steril. 75:(5):2001;992-996.
5. Creasman W.T., Odicino F., Maisonneuve P., Beller U., Benedet J.L., Heintz A.P., et al. Carcinoma of the corpus uteri. J Epidemiol Biostat. 6:(1):2001;47-86.
6. Creasman W.T., Eddy G.L. Recent advances in endometrial cancer. Semin Surg Oncol. 6:1990;339.
7. Cotran RS, Kumar V, Robbins SL. Robbins pathologic basis of disease. 6th ed. Philadelphia: W.B. Saunders Company; 1999, p. 1062.
8. Philip JD, William TC, et al. Clinical gynecologic oncology. 6th ed. St. Louis: Mosby, Inc.; 2002, p. 148-9.
9. Harada H., Takahashi E., Itoh S., Harada K., Hori T.A., Taniguchi T. Structure and regulation of the human interferon regulatory factor 1 (IRF-1) and IRF-2 genes: implications for a gene network in the interferon system. Mol Cell Biol. 14:(2):1994;1500-1509.
10. Um S.J., Kim E.J., Hwang E.S., Kim S.J., Namkoong S.E., Park J.S. Antiproliferative effects of retinoic acid/interferon in cervical carcinoma cell lines: cooperative growth suppression of IRF-1 and p53. Int J Cancer. 85:(3):2000;416-423.
11. Hachisuga T., Fukuda K., Nakamura S., Iwasaka T., Sugimori H. Local immune response in endometrial carcinomas. Br J Obstet Gynaecol. 104:1997;110-114.
12. Ogasawara K., Hida S., Azumi N., Tagaya Y., Sato T., Yokochi- Fukuda T. Requirement for IRF-1 in microenvironment supporting development of natural killer cells. Nature. 391:(6668):1998;700-703. 12.